Roche reports positive Phase II topline data for enicepatide
Roche said it has positive topline results from CT-388-104, a Phase II trial of once-weekly enicepatide (CT-388), a dual GLP-1/GIP receptor agonist, in adults with type 2 diabetes and overweight or obesity.
Story updates
05:05:15 AM UTC
SquawkNews
Genentech Announces Positive Phase II Results for Dual GLP-1/GIP Receptor Agonist Enicepatide in People Living With Type 2 Diabetes and Overweight or Obesity
Basel, 22 September 2026 - Roche (SIX: RO, ROP; OTCQX: RHHBY) said today it has reported positive topline results from CT-388-104, a Phase II clinical trial of enicepatide (CT-388), an investigational once-weekly dual GLP-1/GIP receptor agonist, in adults living with type 2 diabetes (T2D) and overweight…